KRYSTAL BIOTECH INC (KRYS)
Health Care · NASDAQ
Krystal Biotech commercializes VYJUVEK, a gene therapy for dystrophic epidermolysis bullosa, and is developing additional HSV-1 vector-based therapies for rare genetic diseases.
What KRYSTAL BIOTECH INC does
Krystal Biotech is a biopharmaceutical company focused on developing and commercializing gene therapies for patients with rare genetic diseases. The company's lead product, VYJUVEK (beremagene geperpavec-svdt), is an in vivo gene therapy for dystrophic epidermolysis bullosa (DEB) that has been approved by the FDA (May 2023), European Commission (April 2025), and Japan's MHLW (July 2025). Krystal Biotech leverages a proprietary HSV-1 based vector platform to develop additional therapeutic candidates for rare genetic diseases.
Themes: ["Gene therapy / rare genetic diseases","Dystrophic epidermolysis bullosa (DEB)","In vivo gene therapy","Orphan/rare disease treatment"]
Fundamentals
- Price$371.24 as of 2026-07-09 close
- Market cap$10.9B as of 2026-07-10
- 1-year return+149.3% as of 2026-07-09 close
- P/E48.42 as of 2026-07-10
- Net margin+53.9% as of 2026-07-10
- Gross margin+94.2% as of 2026-07-10
- ROE+19.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+25.1% as of 2026-07-10
- Beta0.53 as of 2026-07-10
Key risks (from latest filing)
["Competitive landscape in gene therapy and rare disease treatments, with established biopharmaceutical companies entering the space and potential alternative therapeutic approaches","Manufacturing scalability and commercialization execution risks for proprietary manufacturing methods and processes","Regulatory and reimbursement uncertainty for gene therapies and rare disease products, particularly in international markets"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.